Could ketamine lift depression in palliative care patients?

NCT ID NCT02783430

Completed Symptom relief Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tested whether adding ketamine to the antidepressant milnacipran helps reduce depression in people with severe, progressive diseases (like advanced cancer). 42 hospitalized patients in palliative care received either ketamine plus milnacipran or a placebo plus milnacipran. The goal was to see if the combination improved mood and quality of life more than milnacipran alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

C.H de Roubaix

Roubaix, France
Centre Hospitalier de Valenciennes

Valenciennes, France
Ch Calais

Calais, France
Ch Ghpso Senlis

Senlis, France
Ch Tourcoing

Tourcoing, France
Chu Amiens Picardie

Amiens, France
Groupt Hopitaux Instit Catho de Lille - Lomme

Lomme, France
Maison Medicale Jean Xxiii - Lille

Lille, 59037, France
University Hospital,

Lille, France

Conditions

Explore the condition pages connected to this study.

DEPRESSION